This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Pacira (PCRX) Q2 Earnings Beat, Exparel Sales Drive Revenues
by Zacks Equity Research
Pacira (PCRX) reports better-than-expected second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by higher Exparel sales.
PCRXPositive Net Change ANIPNegative Net Change AKROPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Repligen's (RGEN) Q2 Earnings & Revenues Meet Estimates
by Zacks Equity Research
Repligen's (RGEN) second-quarter earnings and revenues match estimates. The company narrows its revenue guidance for 2024. Stock rises.
UTHRPositive Net Change HALOPositive Net Change RGENPositive Net Change RPTXPositive Net Change
biotechs earnings
Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis' (ZTS) higher companion animal product sales are expected to have driven revenues in the second quarter of 2024 in both the United States and International segments.
BMRNPositive Net Change ZTSPositive Net Change DNLIPositive Net Change APLSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
GSK Beats Q2 Earnings & Sales Estimates, Ups 2024 Guidance
by Zacks Equity Research
GSK's revenues benefit from strong growth across the Specialty Medicines and General Medicines segments. It raises guidance for earnings and sales for the full year.
SNYPositive Net Change GSKPositive Net Change JNJPositive Net Change VIRPositive Net Change
biotechs earnings medical messenger-rna pharmaceuticals vaccines
Merck (MRK) Q2 Earnings & Sales Beat Estimates, Cuts '24 EPS View
by Zacks Equity Research
Merck (MRK) posts better than expected second-quarter results, backed by strong demand for blockbuster cancer drug Keytruda. The stock falls in pre-market trading, likely due to the EPS guidance slash.
AZNPositive Net Change MRKPositive Net Change HALOPositive Net Change TRDAPositive Net Change
biotechs earnings medical pharmaceuticals vaccines
Incyte's (INCY) Q2 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Incyte's (INCY) second-quarter 2024 earnings miss estimates while revenues beat the same. The company raises the bottom end of the 2024 revenue guidance for its lead drug, Jakafi.
NVSPositive Net Change LLYPositive Net Change INCYNegative Net Change HALOPositive Net Change
biotechs earnings
Recursion (RXRX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Recursion (RXRX) is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its second-quarter earnings release, given the absence of a marketed product.
BMRNPositive Net Change DNLIPositive Net Change APLSPositive Net Change RXRXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Vertex (VRTX) Stock Before Q2 Earnings: To Buy or Not to Buy?
by Ahan Chakraborty
Vertex's (VRTX) second-quarter revenues are expected to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.
VRTXNegative Net Change MRNAPositive Net Change CRSPPositive Net Change
biotechnology biotechs crispr earnings-preview medical pharmaceuticals
What Awaits Biogen (BIIB) in Q2 Earnings Post Leqembi Setback?
by Zacks Equity Research
Biogen's (BIIB) sales in the second quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been hurt by increased competition.
BIIBPositive Net Change AMGNNegative Net Change AGENNegative Net Change
biotechs pharmaceuticals
Dr. Reddy's (RDY) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Dr. Reddy's (RDY) reports mixed first-quarter fiscal 2025 results, wherein earnings lag estimates, but revenues beat the same, driven by growth in global generics sales in North America and India.
RDYPositive Net Change RHHBYPositive Net Change RAPTPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Affimed (AFMD) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Affimed's (AFMD) second-quarter 2024 earnings call, investors' focus is likely to be on the progress of its pipeline candidates being developed for various cancer indications.
RHHBYPositive Net Change AMGNNegative Net Change KRYSPositive Net Change
biotechs
5 Biotech Stocks to Bet On Bright Industry Prospects
by Ekta Bagri
New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position MRNA, SRPT, HALO, KRYS and AXSM well in this volatile sector.
MRNAPositive Net Change HALOPositive Net Change SRPTPositive Net Change AXSMPositive Net Change KRYSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Bristol-Myers (BMY) Tops on Q2 Earnings, Ups '24 EPS View
by Zacks Equity Research
Bristol-Myers (BMY) posts impressive second-quarter results, with both earnings and sales beating their respective estimates. The company also raises its annual earnings guidance.
BMYNegative Net Change PFEPositive Net Change CORTNegative Net Change TRDAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical
by Zacks Equity Research
Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical are part of the Zacks top Analyst Blog.
BIIBPositive Net Change BMRNPositive Net Change AGENNegative Net Change
biotechnology biotechs
Intellia (NTLA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Intellia's (NTLA) second-quarter 2024 earnings call, investors' focus is likely to be on the progress of its pipeline of genome-editing candidates.
REGNNegative Net Change AMGNNegative Net Change NTLAPositive Net Change KRYSPositive Net Change
biotechs
Ginkgo (DNA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Ginkgo's (DNA) total revenues are likely to have declined in the second quarter, owing to the expected ramp-down of the company's K-12 COVID testing services.
AMGNNegative Net Change ADVMPositive Net Change KRYSPositive Net Change DNAPositive Net Change
biotechs
Should You Invest in Novo Nordisk (NVO) Ahead of Q2 Earnings?
by Ahan Chakraborty
Novo Nordisk's (NVO) second-quarter revenues are expected to have been driven by its diabetes and obesity care product sales, especially Wegovy, Ozempic and Rybelsus.
RHHBYPositive Net Change NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs earnings-preview medical pe-ratio pharmaceuticals
Moderna (MRNA) Stock Before Q2 Earnings: To Buy or Not to Buy?
by Sundeep Ganoria
Investors will likely focus on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates when it reports second-quarter earnings.
GSKPositive Net Change PFEPositive Net Change MRKPositive Net Change MRNAPositive Net Change
biotechs earnings-preview medical messenger-rna pharmaceuticals vaccines
Viking (VKTX) Q2 Earnings Beat, Stock Up on Pipeline Updates
by Zacks Equity Research
Viking (VKTX) gains 24% on better-than-expected second-quarter 2024 results, along with encouraging updates regarding its pipeline development plans.
ANIPNegative Net Change VKTXPositive Net Change RAPTPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Alkermes' (ALKS) Q2 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Alkermes (ALKS) reports mixed second-quarter 2024 results. Earnings and revenues decline year over year.
ALKSPositive Net Change ANIPNegative Net Change AXSMPositive Net Change RAPTPositive Net Change
biotechs earnings
AbbVie (ABBV) Beats on Q2 Earnings & Sales, Ups '24 EPS View
by Zacks Equity Research
AbbVie's (ABBV) second-quarter earnings and sales beat estimates. Management hikes the EPS guidance on encouraging product sales for immunology drugs.
RHHBYPositive Net Change JNJPositive Net Change ABBVPositive Net Change GMABPositive Net Change
biotechs earnings medical pharmaceuticals
Biotech Stock Roundup: SAGE Plunges on Study Failure, AGEN Down on Regulatory Update & More
by Ekta Bagri
Sage Therapeutics (SAGE) and Agenus (AGEN) are in the spotlight following study failure and regulatory updates, respectively.
BIIBPositive Net Change BMRNPositive Net Change AGENNegative Net Change
biotechnology biotechs medical pharmaceuticals
AstraZeneca (AZN) Beats on Q2 Earnings & Sales, Ups '24 View
by Zacks Equity Research
AstraZeneca (AZN) reports encouraging Q2 results. It also raises its financial guidance for the full year on the back of strong demand for its marketed products.
SNYPositive Net Change AZNPositive Net Change MRKPositive Net Change AMGNNegative Net Change
biotechs earnings medical pharmaceuticals vaccines
GSK Stock Before Q2 Earnings: To Buy or Not to Buy?
by Sundeep Ganoria
We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Trelegy Ellipta and Shingrix to drive second-quarter sales performance.
GSKPositive Net Change JNJPositive Net Change HLNPositive Net Change
biotechs earnings medical pharmaceuticals vaccines
Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?
by Zacks Equity Research
On Incyte's (INCY) second-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its lead drug, Jakafi, which has been facing stiff competition.
NVSPositive Net Change AMGNNegative Net Change INCYNegative Net Change ADVMPositive Net Change
biotechs